What does Gulliver Biomed do?

Gulliver Biomed is a testing and inspection body in Gent. Private Limited, started on 14 March 2018, 1 establishment.

What is the address of Gulliver Biomed?

The registered office of Gulliver Biomed is located at Technologiepark-Zwijnaarde 82, 9052 Gent.

Is Gulliver Biomed still active?

Yes. According to the CBE (2 November 2026) Gulliver Biomed is active, legal situation “Normale toestand”, started on 14 March 2018.

Is Gulliver Biomed registered on Peppol?

Yes, Gulliver Biomed is registered on the Peppol network with ID 0208:0692527837.

What is the enterprise number of Gulliver Biomed?

The enterprise number of Gulliver Biomed is BE0692527837.

When was Gulliver Biomed founded?

Gulliver Biomed was founded on 14 March 2018.

Who are the directors of Gulliver Biomed?

According to the 2025 annual accounts, the directors of Gulliver Biomed are: Jan Christiaan Gettemans.

Is Gulliver Biomed a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 14 March 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Gulliver Biomed make in 2025?

Gulliver Biomed posted a profit after taxes of € 56,888 in financial year 2025.

What is the revenue of Gulliver Biomed?

As a small company, Gulliver Biomed is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 96,191.

Gulliver Biomed (Private Limited) - Gent - BE0692527837

Dossier Gulliver Biomed, printed on 2 November 2026 from databakkes.be/en/0692527837/gulliver-biomed. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

26 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

Gulliver Biomed from Gent, company number BE0692527837, closed financial year 2025 with a result of € 56,888 after tax. For that financial year Gulliver Biomed recorded a gross margin of € 96,191 and equity of € 131,641. Compared with financial year 2024, the result moved from € 53,918 to € 56,888. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 15, 2026.

What it is worth Growing

€ 131,641

▲ 76% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 56,888

▲ 6% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 111,607

▲ 29% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 113,041.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 14,597

▼ 40% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 3,972

▼ 66% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 46,711

▲ € 42,971 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 30,661

▲ 80% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 34,471 Gross margin 2022: € 34,471 First fiscal year in the series	€ 517 Gross margin 2023: € 517 ▼ 99% vs 2022 (€ 34,471) Unfavourable step	€ 72,495 Gross margin 2024: € 72,495 ▲ € 71,978 vs 2023 (€ 517) Favourable step	€ 96,191 Gross margin 2025: € 96,191 ▲ 33% vs 2024 (€ 72,495) Favourable step	▲ 33%
Profit after taxes	€ 21,788 Profit after taxes 2022: € 21,788 First fiscal year in the series	€ -11,437 Profit after taxes 2023: € -11,437 ▼ € 33,225 vs 2022 (€ 21,788) Unfavourable step	€ 53,918 Profit after taxes 2024: € 53,918 ▲ € 65,356 vs 2023 (€ -11,437) Favourable step	€ 56,888 Profit after taxes 2025: € 56,888 ▲ 6% vs 2024 (€ 53,918) Favourable step	▲ 6%
Equity	€ 78,272 Equity 2022: € 78,272 First fiscal year in the series	€ 20,834 Equity 2023: € 20,834 ▼ 73% vs 2022 (€ 78,272) Unfavourable step	€ 74,753 Equity 2024: € 74,753 ▲ 259% vs 2023 (€ 20,834) Favourable step	€ 131,641 Equity 2025: € 131,641 ▲ 76% vs 2024 (€ 74,753) Favourable step	▲ 76%
Total debts	€ 48,705 Total debts 2022: € 48,705 First fiscal year in the series	€ 84,144 Total debts 2023: € 84,144 ▲ 73% vs 2022 (€ 48,705) Unfavourable step	€ 41,813 Total debts 2024: € 41,813 ▼ 50% vs 2023 (€ 84,144) Favourable step	€ 126,419 Total debts 2025: € 126,419 ▲ 202% vs 2024 (€ 41,813) Unfavourable step	▲ 202%
Cash	€ 67,244 Cash 2022: € 67,244 First fiscal year in the series	€ 652 Cash 2023: € 652 ▼ 99% vs 2022 (€ 67,244) Unfavourable step	€ 86,482 Cash 2024: € 86,482 ▲ € 85,830 vs 2023 (€ 652) Favourable step	€ 111,607 Cash 2025: € 111,607 ▲ 29% vs 2024 (€ 86,482) Favourable step	▲ 29%
Retained profit	€ 59,672 Retained profit 2022: € 59,672 First fiscal year in the series	€ 2,234 Retained profit 2023: € 2,234 ▼ 96% vs 2022 (€ 59,672) Unfavourable step	€ 56,153 Retained profit 2024: € 56,153 ▲ € 53,918 vs 2023 (€ 2,234) Favourable step	€ 113,041 Retained profit 2025: € 113,041 ▲ 101% vs 2024 (€ 56,153) Favourable step	▲ 101%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 46,000 Dividend 2023: € 46,000 ▲ € 45,200 vs 2022 (€ 800) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 46,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 26,464 Bank debt 2022: € 26,464 First fiscal year in the series	€ 19,214 Bank debt 2023: € 19,214 ▼ 27% vs 2022 (€ 26,464) Favourable step	€ 11,719 Bank debt 2024: € 11,719 ▼ 39% vs 2023 (€ 19,214) Favourable step	€ 3,972 Bank debt 2025: € 3,972 ▼ 66% vs 2024 (€ 11,719) Favourable step	▼ 66%
Balance sheet total	€ 126,977 Balance sheet total 2022: € 126,977 First fiscal year in the series	€ 104,978 Balance sheet total 2023: € 104,978 ▼ 17% vs 2022 (€ 126,977) Unchanged	€ 116,566 Balance sheet total 2024: € 116,566 ▲ 11% vs 2023 (€ 104,978) Unchanged	€ 258,060 Balance sheet total 2025: € 258,060 ▲ 121% vs 2024 (€ 116,566) Unchanged	▲ 121%

Key figures of Gulliver Biomed, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Gulliver Biomed?

What happened at Gulliver Biomed in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 15, 2026 New annual accounts for financial year 2025: profit of € 56,888 (▲ 6% vs 2024). filed late Source: NBB ↗
2023 Jan Christiaan Gettemans became a director. NBB
Mar 14, 2018 New establishment in Gent. KBO
Mar 14, 2018 Start of the company according to the CBE. KBO

In short

From € 21,788 profit in 2022 to € 56,888 profit in 2025.

Paid € 43,116 in corporate taxes since 2022.

Best year ever: 2025, with € 56,888 profit.

Paid out € 46,800 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Jan Christiaan Gettemans

Gulliver Biomed

Behind Gulliver Biomed is Jan Christiaan Gettemans.

Directors

According to the 2025 annual accounts

Jan Christiaan Gettemans

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Technologiepark-Zwijnaarde 82

9052 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 26 companies are registered at this address.

All companies at this address →

CONTREL EUROPE

€ 250,724 gross margin · 2025

INCUBATIE- EN INNOVATIECENTRUM UNIVERSITEIT

€ 1.4 million gross margin · 2025

VP VENTURES

€ -1,670 gross margin · 2025

SENSNET

Inbiose

€ 6.3 million revenue · 2025

+21 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0692.527.837
VAT number: BE 0692.527.837
Registered office: Technologiepark-Zwijnaarde 82, 9052 Gent
Names & denominations: Gulliver Biomed
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 14 March 2018
Peppol: Active · Active since 4 Feb 2026
Activities · NACE: Overige technische testen en toetsen

View on CBE Public ↗ Annual accounts (NBB) ↗